Identification of Alpha-Adrenergic Agonists as Potential Therapeutic Agents for Dermatomyositis through Drug-Repurposing Using Public Expression Datasets

J Invest Dermatol. 2016 Jul;136(7):1517-1520. doi: 10.1016/j.jid.2016.03.001. Epub 2016 Mar 11.

Authors

Hyunje Grace Cho¹, David Fiorentino², Matthew Lewis², Marina Sirota³, Kavita Y Sarin⁴

Affiliations

¹ School of Medicine, Stanford University, Stanford, California, USA.
² Department of Dermatology, Stanford University Medical Center, Stanford, California, USA.
³ Institute for Computational Health Sciences, University of California San Francisco, San Francisco, California, USA.
⁴ Department of Dermatology, Stanford University Medical Center, Stanford, California, USA. Electronic address: ksarin@stanford.edu.

No abstract available

Publication types

Letter

MeSH terms

Adrenergic alpha-Agonists / therapeutic use*
Datasets as Topic
Dermatomyositis / drug therapy*
Drug Repositioning*
Humans
Oxymetazoline / therapeutic use

Substances

Adrenergic alpha-Agonists
Oxymetazoline

Grant support

T32 AR050942/AR/NIAMS NIH HHS/United States